Quick July 7 and 8 news headlines for the psychadelic biotech $CMPS , a lot of analysts putting their opions out there the past couple of days, thought I'd share with everyone: HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $70 Price Target 1:34 PM ET 7/8/26 | Benzinga Compass Pathways' COMP360 Data Supports FDA Approval Potential, RBC Says 12:36 PM ET 7/8/26 | MT Newswires Evercore ISI Group Upgrades Compass Pathways to Outperform, Raises Price Target to $21 11:47 AM ET 7/8/26 | Benzinga Stifel Maintains Buy on Compass Pathways, Raises Price Target to $21 10:23 AM ET 7/8/26 | Benzinga Morgan Stanley Reiterates Overweight on Compass Pathways, Maintains $17 Price Target 3:57 PM ET 7/7/26 | Benzinga Oppenheimer Reiterates Outperform on Compass Pathways, Maintains $20 Price Target 2:07 PM ET 7/7/26 | Benzinga BTIG Maintains Buy on Compass Pathways, Raises Price Target to $25 1:43 PM ET 7/7/26 | Benzinga
106 views
0 Comments
Join the conversation with 500,000+ other investors 💸
Create an account to get access to everything Blossom has to offer!
📊 Personalized algorithm based on your investing style, experience level and interests
📈 Powerful portfolio and dividend tracking tools
👀 See what top creators and others in the community are investing in
